Product Description: CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual G9a/DNA methyltransferases (DNMTs) inhibitor with antitumor activities. CM-272 inhibits G9a, DNMT1, DNMT3A, DNMT3B and GLP with IC50s of 8 nM, 382 nM, 85 nM, 1200 nM and 2 nM, respectively. CM-272 inhibits cell proliferation and promotes apoptosis, inducing IFN-stimulated genes and immunogenic cell death[1].
Applications: Cancer-programmed cell death
Formula: C28H38N4O3
References: [1]San José-Enériz E, et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat Commun. 2017 May 26;8:15424.
CAS Number: 1846570-31-7
Molecular Weight: 478.63
Compound Purity: 98.70
Research Area: Cancer
Solubility: DMSO : 125 mg/mL (ultrasonic)
Target: Apoptosis;DNA Methyltransferase;Histone Methyltransferase
Deutsch
English
